Idelalisib
Phase 3Terminated 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Follicular Lymphoma
Conditions
Follicular Lymphoma
Trial Timeline
Jan 14, 2016 → Sep 27, 2022
NCT ID
NCT02536300About Idelalisib
Idelalisib is a phase 3 stage product being developed by Gilead Sciences for Follicular Lymphoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02536300. Target conditions include Follicular Lymphoma.
What happened to similar drugs?
1 of 20 similar drugs in Follicular Lymphoma were approved
Approved (1) Terminated (4) Active (15)
Hype Score Breakdown
Clinical
17
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03568929 | Pre-clinical | Completed |
| NCT02739360 | Approved | Terminated |
| NCT02928510 | Pre-clinical | Terminated |
| NCT02536300 | Phase 3 | Terminated |
| NCT02590588 | Phase 2 | Terminated |
| NCT02242045 | Phase 1 | Completed |
| NCT01539291 | Phase 3 | Terminated |
| NCT01393106 | Phase 2 | Completed |
| NCT01282424 | Phase 2 | Completed |
| NCT01306643 | Phase 1/2 | Completed |
| NCT01090414 | Phase 1/2 | Terminated |
Competing Products
20 competing products in Follicular Lymphoma